Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2018-000717-20-DE
EUCTR2018-000717-20-DE
Active, not recruiting
Phase 1

ong-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011

Medigene AG0 sites52 target enrollmentJuly 19, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHigh Risk Myeloid and Lymphoid NeopolasmsMedDRA version: 20.0 Level: PT Classification code 10061240 Term: Malignant lymphoid neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851MedDRA version: 16.1 Level: HLT Classification code 10028229 Term: Multiple myelomas System Organ Class: 100000004851MedDRA version: 20.0 Level: LLT Classification code 10028557 Term: Myeloid leukemia, acute System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10028533 Term: Myelodysplastic syndrome System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
High Risk Myeloid and Lymphoid Neopolasms
Sponsor
Medigene AG
Enrollment
52
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 19, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- Treated with MDG1011 in a Medigene sponsored clinical trial whether completed or not.
  • •\- Signed informed consent for this Long\-term Follow\-up clinical trial
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Subjects who received their last treatment with MDG1011 more than 15 years before the first visit of this Long\-term Follow\-Up clinical trial

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
ong-term clinical follow-up study of patients and families with choroideremia for future clinical trialsCHMChoroideremiatapetochoroideal dystrophy (TCD)1001592010010463
NL-OMON38958Academisch Medisch Centrum50
Not yet recruiting
Not Applicable
ong term follow up of randomised clinical trial on total joint arthroplasty or trapeziectomie for trapeziometacarpal osteoarthritistrapeziometacarpal osteoarthritiscarpometacarpal osteoarthritis10023213
NL-OMON42533Isala Klinieken55
Active, not recruiting
Phase 1
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapieson-small cell lung cancer (NSCLC), Multiple Myeloma & other indications, Synovial sarcoma, Myxoid/round cell liposarcoma (MRCLS)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073137Term: Myxoid liposarcoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042863Term: Synovial sarcoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2024-513033-21-00Adaptimmune LLC76
Active, not recruiting
Phase 1
Adoptive cell therapy LTFU studySynovial sarcomaMultiple myelomaNon-small cell lung cancerMyxoid liposarcomaMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004888-31-NLGlaxoSmithKline research & development Ltd.171
Active, not recruiting
Phase 1
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004888-31-FRGlaxoSmithKline Research & Development Ltd171